欧盟 - 英文 - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human - vaccines - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance.

欧盟 - 英文 - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - influenza vaccines - prophylaxis of influenza caused by a (h1n1v) 2009 virus.focetria should be used in accordance with official guidance.

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (sanofi - influenza virus split virion - suspension for injection

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - influenza virus haemagglutinin -

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; monobasic sodium phosphate; octoxinol 9; dibasic sodium phosphate - fluquadri is indicated for active immunisation of influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine.,fluquadri is indicated for use in adults and children 6 months and older.

欧盟 - 英文 - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human; immunization; disease outbreaks - vaccines - active immunisation against h5n1 subtype of influenza a virus.this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared from a/vietnam/1194/2004 nibrg-14 (h5n1) (see section 5.1).prepandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals 3.75 µg should be used in accordance with official guidance.

欧盟 - 英文 - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vaccines - active immunisation against h5 subtype of influenza a virus

马耳他 - 英文 - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - influenza vaccine, split virion, inactivated - suspension for injection - influenza vaccine (split virion, inactivated) 15 µg - vaccines

马耳他 - 英文 - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - influenza vaccine, split virion, inactivated - suspension for injection in pre-filled syringe - influenza vaccine (split virion, inactivated) a/victoria/4897/2022 (h1n1) pdm09 - like strain (a/victoria/4897/2022 ivr-238 15 µg a/darwin/9/2021 (h3n2) - like strain (a/darwin/6/2021, ivr-227 15 µg b/austria/1359417/2021 - like strain (b/austria/1359417/2021 bvr-26 15 µg b/phuket/3073/2013 - like strain (b/phuket/3073/2013, wild type) - vaccines

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

au pharma pty ltd - influenza virus haemagglutinin, quantity: 15 microgram/ml - injection, suspension - excipient ingredients: trometamol; water for injections; sodium chloride; polysorbate 80 - pandemic influenza vaccine h5n1 baxter is indicated for prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official recommendations.